Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 356 Cr.
- Current Price ₹ 310
- High / Low ₹ 339 / 144
- Stock P/E 33.9
- Book Value ₹ 56.1
- Dividend Yield 0.00 %
- ROCE 24.3 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 102 to 56.4 days.
- Company's working capital requirements have reduced from 233 days to 129 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.8.23 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 22 | 32 | 45 | 87 | |
| 19 | 25 | 36 | 72 | |
| Operating Profit | 3 | 6 | 8 | 15 |
| OPM % | 12% | 20% | 18% | 17% |
| 1 | 1 | 2 | 8 | |
| Interest | 0 | 0 | 1 | 4 |
| Depreciation | 0 | 0 | 1 | 5 |
| Profit before tax | 3 | 7 | 9 | 14 |
| Tax % | -32% | 8% | 32% | 23% |
| 4 | 6 | 6 | 10 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 59% |
| TTM: | 95% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 |
| 2 | 8 | 18 | 54 | |
| 7 | 9 | 16 | 38 | |
| Total Liabilities | 14 | 63 | 87 | 156 |
| 1 | 3 | 21 | 44 | |
| CWIP | 0 | 5 | 4 | 2 |
| Investments | 0 | 3 | 4 | 11 |
| 12 | 51 | 58 | 100 | |
| Total Assets | 14 | 63 | 87 | 156 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -19 | 2 | -10 | |
| -0 | -10 | -20 | -14 | |
| 1 | 42 | 11 | 20 | |
| Net Cash Flow | 0 | 14 | -7 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | |
| Inventory Days | 95 | 129 | 156 | |
| Days Payable | 134 | 87 | 94 | |
| Cash Conversion Cycle | 44 | 182 | 173 | |
| Working Capital Days | 67 | 319 | 251 | |
| ROCE % | 23% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4h - Trident Lifeline Limited hereby enclose copies of newspaper advertisement published on April 30, 2025 regarding extract of the Audited Standalone and Consolidated Financial Statements for …
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
1d - Trident Lifeline confirms not classified as 'Large Corporate' per SEBI circular as of 31.03.2025.
-
Non-Applicability Of Regulation 23(9) Of SEBI (Listing Obligation & Disclosures Requirements) Regulation, 2015 For March 31, 2025
1d - Trident Lifeline exempt from SEBI Reg 23(9) disclosures for H1 FY25 due to SME listing.
-
Integrated Filing (Financial)
1d - Audited FY 2025 financial results approved; internal auditor DAC & Co. appointed for FY 2025-26.
-
Statement Of Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (LODR)
Regulations, 2015
1d - IPO fund utilization statement as of Mar 31, 2025 shows no deviation; audited and reviewed by committee.
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities